Form 4: ClearPoint Neuro Director Acquires Shares

ClearPoint Neuro, Inc. Director B. Kristine Johnson acquired 12,417 shares of common stock upon the vesting of restricted stock units.

Summary

• B. Kristine Johnson, a Director at ClearPoint Neuro, Inc., acquired 12,417 shares of common stock.
• The acquisition occurred on May 19, 2026, as a result of the vesting of restricted stock units (RSUs).
• These RSUs were granted on May 22, 2025, and vested on the first anniversary of the grant date, which coincided with the day before the company's 2026 annual meeting of stockholders.
• Following this transaction, B. Kristine Johnson beneficially owns 71,116 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard insider transaction (vesting of RSUs) rather than a new strategic development or financial performance indicator.

Positives

• Director B. Kristine Johnson's beneficial ownership of ClearPoint Neuro, Inc. common stock increased.
• The acquisition of shares through RSU vesting indicates a commitment and reward for company leadership.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which details a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, reflecting normal compensation and ownership adjustments for company directors and officers. This filing indicates a routine vesting event for a ClearPoint Neuro director.

Stakeholder Impact

• Shareholders: The acquisition by a director does not immediately impact share price but reflects ongoing compensation structures and insider confidence.

Key Dates

Keywords

ClearPoint Neuro, CLPT, Form 4, Insider Trading, Stock Vesting, Restricted Stock Units, Director Compensation, Beneficial Ownership